Article
Medicine, General & Internal
Mehul Gupta, Igor Stukalin, Daniel Meyers, Sid Goutam, Daniel Y. C. Heng, Tina Cheng, Jose Monzon, Vishal Navani
Summary: This study evaluated the treatment-free survival (TFS) outcomes for patients with advanced melanoma receiving first-line immune checkpoint inhibitor (ICI) therapy. The findings suggest that patients treated with combination nivolumab-ipilimumab had better outcomes in terms of time and survival compared to those treated with anti-PD-1 monotherapy alone.
Article
Dermatology
Chang Gon Kim, Miso Kim, Jieon Hwang, Seung Tae Kim, Minkyu Jung, Kyoo Hyun Kim, Kyung Hwan Kim, Jee Suk Chang, Woong Sub Koom, Mi Ryung Roh, Kee Yang Chung, Tae Min Kim, Sang Kyum Kim, Jeeyun Lee, Sang Joon Shin
Summary: This study compared the outcomes of first-line pembrolizumab and dabrafenib/trametinib treatment for patients with advanced melanoma with BRAF mutations. The results showed that first-line pembrolizumab treatment resulted in longer overall survival, suggesting it may be a better treatment option.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Oncology
Meghali Goswami, Gege Gui, Laura W. Dillon, Katherine E. Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y. Ghannam, Karolyn A. Oetjen, Christin B. Destefano, Dana M. Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L. Marte, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L. Gulley, Katherine R. Calvo, Catherine Lai, Christopher S. Hourigan
Summary: This study aimed to investigate the feasibility and efficacy of the combination of PD-1 blockade and hypomethylating therapy in patients with R-AML. The results showed that this combination therapy achieved disease stability or better response in some patients. Moreover, clonal T cell expansions and immunological changes were observed during treatment, which may be associated with treatment-related adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Yousef Zakharia, Robert R. McWilliams, Olivier Rixe, Joseph Drabick, Montaser F. Shaheen, Kenneth F. Grossmann, Ravindra Kolhe, Rafal Pacholczyk, Ramses Sadek, Lucinda L. Tennant, Christopher M. Smith, Eugene P. Kennedy, Charles J. Link, Nicholas N. Vahanian, Jiayi Yu, Steven S. Shen, Erik L. Brincks, Gabriela R. Rossi, David Munn, Mohammed Milhem
Summary: The combination therapy of indoximod and pembrolizumab showed promising anti-tumor efficacy in advanced melanoma patients, especially in PD-L1 positive patients. The treatment was well tolerated with expected side effects similar to pembrolizumab alone.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Piotr Rutkowski, Anna M. Czarnecka
Summary: Up to 30% of stage IIB and 50% of stage IIC melanoma patients experience recurrence within 5 years after radical surgery. Pembrolizumab treatment significantly reduces the risk of recurrence and distant metastases in resected stage II melanoma, showing important efficacy for stage IIB/C patients.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Oncology
Xingxing Hao, Louis D. Falo III, Guo Chen, Jiying Zhang, Cara D. Carey, Walter J. Storkus, Louis D. Falo Jr, Zhaoyang You
Summary: The development of novel strategies to effectively treat patients with melanomas that are resistant to anti-PD1 mAb and/or Brafi, particularly those with multifocal/disseminated disease, is an unmet clinical need. In a study on mice with induced/spontaneous Braf(V600E)/Pten(-/-) melanomas, vaccination with a DNA vaccine encoding TRP2 led to durable antitumor immunity and sensitized PD1-resistant melanomas to salvage therapy with alpha PD1. The therapeutic efficacy of the vaccine was associated with the induction of a systemic, broadly reactive IFN gamma(+)CD8(+) T cell repertoire, increased frequencies of CD8(+) TIL, and reduced levels of PD1(hi/int)CD8(+) T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Giulio Rizzetto, Edoardo De Simoni, Elisa Molinelli, Annamaria Offidani, Oriana Simonetti
Summary: A narrative review was conducted to assess the efficacy evidence of pembrolizumab in the treatment of metastatic melanoma. It was found that pembrolizumab could increase survival in patients with this condition. However, not all patients respond to pembrolizumab, indicating the need for further evaluation of new combination therapies and personalized vaccines.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Georgia M. Beasley, Smita K. Nair, Norma E. Farrow, Karenia Landa, Maria Angelica Selim, Carol Ann Wiggs, Sin-Ho Jung, Darell D. Bigner, Andrea True Kelly, Matthias Gromeier, April K. S. Salama
Summary: In a phase I trial of intratumoral PVSRIPO in patients with unresectable melanoma, the treatment was well tolerated with promising antitumor activity, showing no serious adverse events reported and achieving an objective response rate of 33%, with some patients experiencing complete response in both injected and uninjected lesions.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Tejus Satish, Shaheer Khan, Matt Levin, Richard Carvajal, Angela J. Yoon
Summary: In this case, a patient with oral mucosal melanoma recurred despite multiple resections and adjuvant temozolomide, but achieved complete histopathologic remission with the combination of topical imiquimod and pembrolizumab, demonstrating the potential efficacy of this combined treatment for oral melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Editorial Material
Medicine, General & Internal
Xavier Pivot
Summary: The study confirms the efficacy of pembrolizumab combined with chemotherapy in prolonging overall survival of patients with advanced triple-negative breast cancer, providing a breakthrough therapeutic treatment for this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Caroline A. Nebhan, Douglas B. Johnson
Summary: Anti-PD-1 therapy with pembrolizumab or nivolumab has become the standard of care for resected stage III or IV melanoma patients, regardless of BRAF mutation status.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Article
Oncology
Jalal Siddiqui, Wayne O. Miles
Summary: Studies have shown that RNA editing as a molecular marker for predicting response to immunotherapy has high accuracy and confidence, and can clearly distinguish melanoma patients who are sensitive to immunotherapy.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Hematology
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.
Article
Oncology
Lei Fu, Hui Zhang, Jingwen Jiang, Xuewu Chen, Lang Chen, Hui Gong
Summary: The study found that PEM can improve the short-term clinical effective recovery rate, long-term survival time, and prognosis survival rate of patients with cutaneous malignant melanoma, with no increased incidence of drug-related adverse reactions.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)